Cocrystal Pharma, Inc.

For the period ended Mar 31, 2026. Filed May 15, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 15, 2026

COCP$1.03-6.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except per share data)

	March 31, 2026	December 31, 2025
(unaudited)
Assets
Current assets:
Cash	$4,685	$7,025
Restricted cash	75	75
Grant receivable	70	-
Tax credit receivable	691	706
Prepaid expenses and other current assets	418	328
Total current assets	5,939	8,134
Property and equipment, net	81	93
Deposits	95	95
Operating lease right-of-use assets, net (including $89 and $152 to related party)	1,311	1,390
Total assets	$7,426	$9,712
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and accrued expenses	$1,886	$1,876
Current maturities of operating lease liabilities (including $58 and $49 to related party)	343	334
Total current liabilities	2,229	2,210
Long-term liabilities:
Operating lease liabilities (including $32 and $104 to related party)	1,081	1,171
Total long-term liabilities	1,081	1,171
Total liabilities	3,310	3,381
Commitments and contingencies	-	-
Stockholders’ equity:
Common stock, $0.001 a par value: 100,000 shares authorized as of March 31, 2026 and December 31, 2025; 13,787 and 13,784 shares issued and outstanding as of March 31, 2026 and December 31, 2025	13	13
Additional paid-in capital	348,651	348,567
Accumulated deficit	(344,548)	(342,249)
Total stockholders’ equity	4,116	6,331
Total liabilities and stockholders’ equity	$7,426	$9,712

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.